3种药物膀胱灌注预防膀胱癌术后复发的最小成本分析

Cost - Minimization Analysis of Three Drugs Administered by Bladder Instillation for Prevention of Postoperative Recurrence of Bladder Cancer

目的:评价3种药物膀胱灌注预防膀胱癌术后复发的经济学效果。方法:126例经尿道行膀胱肿瘤电切术后的浅表性膀胱癌患者分为3组,分别采用30 mg吡柔比星溶于40 mL生理盐水、20 mg羟基喜树碱溶于40 mL生理盐水、20 mg丝裂霉素溶于40 mL生理盐水进行膀胱内灌注治疗,总疗程12个月。随访3～24个月,观察复发率,并进行药物经济学分析。结果:THP、HCPT、MMC组复发率分别为18.18%、21.43%、20.00%(P>0.05),医疗总费用分别为15 924.36、12 018.36、8 580.36元。结论:MMC组方案较佳。

OBJECTIVE： To evaluate the economic effects of 3 drugs administered by bladder instillation in the prevention for postoperative recurrence of bladder cancer. METHODS： A total of 126 patients with superficial bladder cancer after transurethral electroresection of bladder tumor （TURBT） were enrolled and randomly assigned to receive 30 mg THP, 20 mg HCPT or 20 mg MMC dissolved in 40 mL sodium chloride by bladder instillation for 12 months. All patients were followed up for 3--24 months. The recurrence of bladder cancer was observed and the pharmacoeconomic analysis was conducted. RE- SULTS： The tumor recurrent rates in THP group, HCPT group and MMC group were 18.18% , 21.43% and 20.00% , respectively（P 〉 0.05）, and the total medical costs were 15 924.36 yuan, 12 018.36 yuan and 8 580.36 yuan, respectively. CONCLUSION： Group MMC is the preferable one among the three groups.